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Abstract
Objective: Although reproductive function is influenced by season, few studies have evaluated 
seasonal effects on menopausal symptoms. We assessed the impact of season and proximity to the 
final menstrual period (FMP) on frequency of symptom reporting.
Methods: 955 participants in the Study of Women’s Health Across the Nation recorded whether 
or not they had experienced menopausal symptoms on a monthly menstrual calendar over a 10-
year period. We modeled the log-odds of presence of a given symptom each month using a logistic 
mixed effects model, assuming a 3rd-order polynomial before the FMP and a different 3rd-order 
polynomial after the FMP. We assumed sine and cosine functions for month of the year.
Results: 5–10 years prior to the FMP, ~20% of women reported hot flashes and night sweats 
while ~40% reported trouble sleeping. Prevalence rose ~4 years before the FMP with a sharp jump 
in hot flash (~60%) and night sweats (~40%) prevalence coincident with the FMP. Peaks in hot 
flashes and trouble sleeping were observed in July with troughs in January. The peak and trough in 
night sweats occurred about one month earlier. Odds of hot flashes, night sweats and trouble 
sleeping were 66%, 50% and 24% greater, respectively, at the seasonal peak versus the seasonal 
minimum.
Corresponding author: Sioban D. Harlow, Department of Epidemiology, University of Michigan, 1415 Washington Heights Suite 
6610, Ann Arbor, MI 48109-2029, 734-763-5173 (phone), 734-936-9271 (FAX), harlow@umich.edu. 
Publisher's Disclaimer: Disclaimer: The content of this article is solely the responsibility of the authors and does not necessarily 
represent the official views of the NIA, NINR, ORWH or the NIH.
Financial disclosures/conflicts of interest:
SDH: American Reagent (Medical Advisory Board); RCT: Pfizer, Proctor and Gamble, MAS Innovations (consulting); ME,IB, EAJ 
report no conflicts of interest.
HHS Public Access
Author manuscript
Menopause. Author manuscript; available in PMC 2021 January 01.
Published in final edited form as:
Menopause. 2020 January ; 27(1): 5–13. doi:10.1097/GME.0000000000001420.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Conclusion: Menopausal symptoms exhibit seasonal variation associated with the summer and 
winter equinoxes. Seasonal increases in night sweats precede increases in hot flashes. 
Prospectively recorded monthly symptom data demonstrate that hot flashes and night sweats 
increase notably coincident with the FMP.
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INTRODUCTION
Several aspects of reproductive function vary by season including probability of birth, 
conception and early pregnancy loss, onset of menarche and menopause, menstrual cycle 
length, follicular phase length and sex steroid hormone levels in humans (1–8). The impact 
of light and dark cycles mediated through melatonin is one mechanism through which 
season influences reproduction but seasonal effects are likely influenced by multiple social 
and environmental mechanisms including food availability and activity (1, 9, 10).
A hallmark of menopause is the onset of vasomotor symptoms including hot flashes and 
night sweats, with up to 80% of women reporting at least some such symptoms (11, 12). 
However, few studies have considered the impact of season on menopausal symptom 
reporting, or accounted for seasonal variation when evaluating symptom prevalence or their 
timing in relation to the final menstrual period (FMP), a major determinant of these 
symptoms. Sievert and colleagues reported cross-country differences in the reporting of hot 
flashes, with more hot flashes reported in regions with colder mean temperatures and greater 
temperature variation, consistent with living at latitudes with greater variability in daylight 
hours. (13). Hunter and colleagues reported cross-country differences in hot flash reporting 
in Latin America and Spain, with higher temperatures and lower altitudes associated with 
increased prevalence (14). However, neither temperature nor temperature variation were 
associated with hot flashes or night sweats in two single country studies (15, 16). A national 
survey in the United States reported that some, but not all, women reported more symptoms 
in the summer (17). All of these studies were cross-sectional (13, 17) or included at most 
two time-points (14–16). Investigating this question in a longitudinal context is critical, as it 
enables investigation of symptom fluctuations over time and seasons within individual 
woman, thereby reducing potential confounding associated with assessing different 
individuals across seasons.
More studies have examined seasonal variability in sleep and sleep problems, but findings 
are inconsistent. For example, two Norwegian studies in adults reported increased difficulty 
initiating sleep in December compared to June (18, 19), a Finnish study reported worse sleep 
quality in the summer (20), while a third Norwegian study reported no monthly variation in 
reported insomnia (21). One cross-sectional US study found that pre-menopausal women 
reported more trouble sleeping in the November-January quarter than in the May-July 
quarter (22). We identified no studies focused on sleep complaints and seasonality in relation 
to menopause.
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The multi-racial/ethnic Study of Women’s Health Across the Nation (SWAN) Menstrual 
Calendar sub-study prospectively ascertained information on menopausal symptoms 
monthly over a 10-year period, providing a unique opportunity to evaluate the role of season 
in symptom reporting. The monthly calendar data also make it possible to more precisely 
model the trajectory of change in symptoms in relation to the FMP.
METHODS
As described elsewhere (23), the Study of Women’s Health Across the Nation (SWAN) is a 
cohort study that has followed a multiethnic sample of 3302 midlife women as they 
transitioned from pre- to post-menopause. In brief, in 1996 seven clinical sites recruited a 
sample of white women and women from one specified minority group (African Americans 
in Pittsburgh, Boston, southeastern Michigan, and Chicago; Japanese in Los Angeles; 
Chinese in Oakland; and Hispanic women in Newark). Eligibility for enrollment into the 
cohort included being 42–52 years of age, having an intact uterus and at least one ovary, 
having had a menstrual period and no use of reproductive hormones in the previous 3 
months, and self-identification in the targeted racial/ethnic groups of the clinical site. 
Women were followed approximately annually, with each visit including an interviewer-
administered and self-administered questionnaire that ascertained information on menstrual 
characteristics, socio-demographic characteristics, lifestyle, and medical history as well as 
physical assessments and a blood draw. In addition, women kept a menstrual calendar that 
ascertained information on menstrual bleeding daily and on symptoms and hormone use 
(HT) monthly. The Menstrual Calendar sub-study was continued through 2006. Institutional 
Review Boards at each study site approved the protocol, and women provided written 
informed consent.
This study includes data from Menstrual Calendar sub-study participants at four study sites 
(Boston, southern Michigan, Oakland, and Los Angeles). Of the 1950 women enrolled at 
these sites, 1883 (96.6%) participated in the menstrual calendar sub-study. To be eligible for 
this analysis, women had to have an observed FMP as the study indexes women’s symptom 
experience in relation to the date of the FMP. A total of 959 (52.3%) women had an 
observed FMP in the Menstrual Calendar sub-study. A woman’s FMP was not observed if 
she had a hysterectomy or double oophorectomy, was lost to follow-up prior to her FMP or 
had not reached her FMP by 2006, or when her FMP was masked by HT use.
Menstrual and Symptom Calendar.
Participants filled out the menstrual calendars daily to capture days when spotting or 
bleeding occurred. On the last day of each month women answered questions about HT use 
and gynecological procedures which could affect their bleeding reports and completed a 
short questionnaire about whether they had experienced six symptoms in the past month 
including the three symptoms that are the focus of this analysis – hot flashes or flushes, 
night sweats, and trouble sleeping. Women were asked to complete the menstrual calendar 
monthly for at least 2 years after their last menstrual bleed.
The final menstrual period (FMP) was defined as the first day of the bleeding episode that 
was followed by at least 12 months of amenorrhea. For women who had missing calendars 
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during the 12 months of amenorrhea, we accepted the FMP observed in the menstrual 
calendar if the date was less than 31 days different from the FMP date identified by 
retrospective recall in the annual interview or if there were two or fewer missing calendars 
during the 12 months of amenorrhea. In this analysis time is indexed to the FMP, as months 
before or after the FMP. Hot flashes or flushes, night sweats, and trouble sleeping were 
coded as a binary variables (yes/no) for each month of observation. HT use was time-
varying, with current use (yes/no) coded for each month of observation.
Baseline Covariates.
Ethnicity was self-defined as African American, Chinese, Japanese, or white. Women were 
asked about their highest level of education (high school graduate/GED or less than high 
school versus at least some college), their smoking status (never, current, past). Financial 
strain was ascertained by the question “how hard is it to pay for basics” (very hard, 
somewhat hard, or not hard). Height and weight were measured without shoes, and in light 
indoor clothing and body mass index (BMI) was calculated as weight in kilograms divided 
by height in meters squared.
Analysis.
The 959 women contributed a total of 64,501 monthly calendars. We excluded 1858 
observations that were >8 years prior to or >4 years after the FMP due to data sparseness 
and 64 post-hysterectomy observations, leaving 62,579 eligible observations from 955 
women. Seventeen women were missing baseline covariate data, leaving 938 women eligible 
for the adjusted regression analyses. Additional observations were excluded in analyses for 
each outcome due to the missingness in the outcome variable (hot flash n=1327; night 
sweats n= 1542, and trouble sleeping n=1392) leaving 58553 observations from 935 women 
for the hot flash analyses, and 58338 and 58488 observations from 934 women for the night 
sweats and trouble sleeping analyses, respectively.
In descriptive analyses, we plotted frequency of symptoms by calendar month and by 
ovarian age (time before and after the FMP). Plots by calendar month suggested seasonality 
and plots by ovarian age suggested a sharp change in probability of symptoms coincident 
with the FMP. We modeled the log-odds of presence of a given symptom each month using a 
logistic mixed effects models. For ovarian age, we assumed a 3rd-order (cubic) polynomial 
before FMP and a different 3rd-order polynomial after FMP. For calendar month, we 
assumed sine and cosine functions for month of the year normalized to lie between 0 and 2π 
by multiplying month (January=1, February=2, etc.) by 2π/12. We graph this effect of 
season to facilitate interpretation of the magnitude of the seasonal effect modelled by the 
sine and cosine functions. We allowed for the cubic polynomial to be disjoint at the time of 
FMP to assess whether there was evidence of a rapid change in probability of a symptom at 
the first month after FMP. To account for correlation between observations from the same 
subject we included subject-specific random effects through the 2nd-degree (quadratic) 
polynomial before and after FMP.
We assessed the effect of concurrent exogenous reproductive hormone use on the likelihood 
of having a symptom after controlling for time trends and seasonality (Models 1 in Table 2). 
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We next constructed models adjusted for covariates, retaining in the final model variables 
that had a statistically significant impact (p<0.05) on the probability of at least one of the 
three symptoms after controlling for time to FMP, seasonality and HT use (Models 2 in 
Table 2). We tested potential interactions between season and site and season and race/
ethnicity. Finally, we tested whether the effect of concurrent HT use interacted with 
menopausal status (before/after FMP).
RESULTS
The 955 women included in this analysis had a mean age at FMP of 51.6 years (standard 
deviation (SD) = 0.08) and a mean BMI of 26.5 kg/m2 (SD = 0.23). Baseline characteristics 
of the participants are presented in Table 1. Reflecting the race/ethnic distribution of the 
enrolled cohort, 42% of participants were white, 26% were black, 15% were Chinese and 
17% were Japanese. Approximately one-quarter of the women had only a high school 
education or less, one-third had some college, and 45% had completed college or higher. 
One third of the women reported having a very or somewhat hard time paying for basics. 
One quarter were past smokers and 15% were current smokers. Over the study period, HT 
use was reported by 22% of women.
Difference in latitude across sites is small ranging from 34.0 in Los Angeles to 42.3 in 
Boston and southeast Michigan. Average July temperatures vary from 12 to 19 degrees 
Celsius (lows) and 19 to 29 degrees (highs). Average January temperatures vary more, from 
−7 to 9 degrees (lows) and 0 to 20 degrees (highs).
Figure 1 presents the prevalence of women reporting hot flashes, night sweats and trouble 
sleeping by month before and after the FMP. Approximately 20% of women report hot 
flashes five to eight years prior to the FMP. The prevalence began rising approximately four 
years before the FMP reaching about 48% of women reporting hot flashes each month in the 
year before the FMP. A sharp rise in reporting occurred at the time of the FMP as 
approximately 60% reported hot flashes each month in the year after the FMP. The 
prevalence declined slowly thereafter. A similar baseline prevalence and pattern of change 
was observed for night sweats, although the increase in prevalence was less, being 
approximately 30% and 40% immediately before and after the FMP, respectively. For 
trouble sleeping, the baseline prevalence was higher, approximately 40%, and the magnitude 
of the rises before and after the FMP were smaller than for either hot flashes or night sweats.
Table 2 presents the results of the regression analyses estimating the monthly odds of 
reporting each symptom. For each symptom, we present the models incorporating only time, 
season, and HT use (Model 1) as well as models additionally adjusted for age at menopause, 
race/ethnicity, smoking status and BMI (Model 2). Reporting of all three symptoms varies 
by season as is indicated by the significant odds ratios (OR) for the sine and co-sine terms 
with the magnitude of this seasonal effect illustrated in Figure 2. A peak in hot flash reports 
was observed in July and a trough in January consistent with the timing of the solstices, with 
peaks in night sweats occurring about one month earlier. The peak and trough for trouble 
sleeping were observed at approximately the same times as hot flashes but were of smaller 
magnitude. Women had a 66% greater odds of a hot flash at their seasonal peak versus their 
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seasonal minimum in both the unadjusted model and the model adjusted for smoking, race, 
age at FMP, and BMI, since season is observed for each woman throughout follow-up and is 
largely independent of other factors. The corresponding percentages for night sweats and 
sleep problems were 50% and 24%, respectively. We detected an interaction between season 
and ethnicity such that a stronger seasonal effect for hot flashes observed among Japanese 
women (cosine OR=0.67, sine OR=0.79, p<0.0001) and stronger seasonal effects for night 
sweats observed among Japanese (cosine OR=0.64, sine OR=0.88, p<0.0001) and, to a 
lesser extent, Chinese women (cosine OR=0.76, sine OR=0.88, p<0.0001).
The odds of reporting all three symptoms increased as women approach the FMP as 
evidenced by the significant squared and cubed terms for time before the FMP. To provide a 
visual interpretation of these regression results accounting for seasonal effects, Figure 3 
illustrates the estimated within-woman trend in the probability of reporting each symptom in 
relation to time to the FMP by smoking status at baseline, by race/ethnicity, and by the time-
varying current HT use. The odds of symptom reporting jumped sharply at the time of the 
FMP, as evidenced in Table 2 by the second intercept for the post-FMP time variable, with 
the odds then declining with increasing time post the FMP. An interaction was present 
between HT and time in relation to the FMP. HT was associated with a decreased odds of 
hot flashes before the FMP, and an even stronger decrease in the odds of hot flashes, after 
the FMP [OR prior to FMP=0.58 (95% CI= 0.45, 0.75); OR post FMP=0.10 (95% CI= 0.06, 
0.15)] (red lines Figure 3C). Prior to the FMP, HT was not associated with the odds of night 
sweats or sleeping trouble, but it was associated with decreased odds of reporting these 
symptoms after the FMP [OR for night sweats post FMP=0.29 (95% CI= 0.18, 0.47) and for 
trouble sleeping post FMP=0.26 (95% CI= 0.17, 0.39)].
Adjusting for additional covariates had little impact on the odds ratios for season or time but 
the odds ratio for HT use prior to the FMP was attenuated in the hot flash model. Additional 
factors associated with symptom reporting were smoking, race/ethnicity, age, and BMI. 
Specifically, current smoking was associated with more than a two-fold increase in the odds 
of hot flashes and night sweats, and an 80% increase in the odds of trouble sleeping. 
Reporting of all three symptoms are more likely among current smokers (green lines Figure 
3A). Compared to White women, Black women had an 80% increase in the odds of 
reporting hot flashes, Japanese women had a 50% to 70% decrease in the odds of reporting 
symptoms, while Chinese women were 50% less likely to report night sweats. Similar 
symptom patterns are present by race/ethnicity, but Black women (blue lines Figure 3B) are 
most likely and Japanese women (brown lines) are least likely to report hot flashes and night 
sweats, whereas white women (red lines) are most likely to report trouble sleeping across 
time. The odds of hot flashes increased also with age at FMP and with higher BMI.
DISCUSSION
Based on prospectively recorded monthly reports of menopausal symptoms in the SWAN 
Menstrual Calendar sub-study, this analysis documented that the reporting of hot flashes, 
night sweats and trouble sleeping varied by season, with peaks in reporting occurring around 
the time of the summer solstice (longest period of daylight) and troughs occurring around 
the time of the winter solstice (shortest period of daylight). Notably, we also documented 
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prospectively a sharp increase in symptom occurrence coincident with the FMP. As 
expected, HT was associated with decreased odds of hot flashes, however the magnitude of 
this effect was stronger after than before the FMP while only use after the FMP was 
associated with decreased odds of night sweats and trouble sleeping.
Despite a large body of work documenting seasonal variation in many aspects of 
reproductive function, few studies have examined seasonality of menopausal symptoms. One 
multi-country study reported that hot flashes were more frequent in regions with colder 
mean temperatures and greater temperature variation, consistent with latitudes having 
greater variability in daylight hours (13). Another multi-country study found that hot flash 
reporting was associated with higher temperatures (14). Two single country studies reported 
no association with temperature or temperature variation (15–16). One national study from 
the US reported that some, but not all, women reported more symptoms in the summer (17).
The literature on seasonal variability in sleep problems is inconsistent and dependent on the 
dimension of sleep examined. In two Norwegian studies, adults reported increased difficulty 
initiating sleep in December compared to June (18, 19). A Finnish study reported worse 
sleep quality in the summer (20), while another Norwegian study reported no monthly 
variation in reported insomnia (21). In contrast to our findings, a cross-sectional analysis of 
a subset of pre-menopausal women only in SWAN found that women assessed in the 
November-January quarter reported more trouble sleeping than did women assessed in the 
May-July quarter (22). Data on seasonality of menopausal sleep complaints are lacking.
Availability of prospectively recorded monthly symptom information from the SWAN 
Menstrual Calendar sub-study for up to 10 years permitted us to evaluate the impact of 
season on symptom reporting within-women longitudinally. We observed seasonal patterns 
in reporting of hot flashes, night sweats and trouble sleeping, with peaks in the summer near 
the solstice, consistent with results for hot flashes in the national US study (17) and for sleep 
quality in the Finnish study (20). The four sites in our study have little variation in latitude 
but meaningful variation in temperature, especially in the winter months.
Notably, although the underlying physiology of hot flashes and night sweats are not fully 
understood, leading models indicate that they are thermoregulatory events, or dramatic heat 
dissipation events in the context of altered hypothalamic thermoregulatory functioning in 
symptomatic menopausal women (24). Thus, higher ambient temperature may increase the 
likelihood of hot flashes and night sweats, with some laboratory data supportive of that 
hypothesis (25). However, effects of season did not differ by site (which varied markedly in 
temperature), suggesting that the observed seasonality in symptom reporting was not driven 
solely by temperature alone. Other potential stimuli include temperature changes rather than 
absolute levels, or changes in light.
Freedman and colleagues suggest women experiencing VMS have a smaller thermoneutral 
zone compared to those with no VMS (26), thus small temperature changes may easily 
provoke hot flashes or night sweats in symptomatic women. Hot flashes have been linked to 
sleep disturbances, particularly early in the night. One hypothesis is that rapid eye movement 
(REM) sleep stages may reduce thermoregulatory responses leading to reduced VMS (27). 
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The circadian regulation of body temperature, a highly complex system influenced by 
numerous factors, is increasingly unstable with aging (28).
Notably, the hypothalamus houses not only thermoregulatory centers but also the 
superchiasmatic nucleus, a pacemaker which is entrained in part by light, and integrally 
involved in the control of circadian rhythms across a range of physiologic processes. Light 
inhibits secretion of melatonin. Melatonin helps regulate the circadian clock and thus sleep. 
Melatonin also plays an important, although not fully understood, role in neuroendocrine 
regulation. It down regulates reproductive function, inhibits luteinizing hormone and may 
inactivate the gonadotropin releasing hormone pulse generator (29–31). Longer winter 
nights are associated with increased and more prolonged melatonin secretion, thus 
susceptible women may experience changes in melatonin-regulated phenomena associated 
with lengthening hours of daylight (31). With aging and with the transition to menopause, 
melatonin levels decrease, especially at night (29, 30, 32). Thus, the increase in sleep 
complaints during this lifestage may in part be attributable to this decrease in melatonin 
levels (29,30). Evidence for a direct effect of melatonin on vasomotor symptoms is lacking 
(30,31) but may be associated with the increase in sleep disorders. Advances in scientific 
understanding of the underlying physiology of vasomotor symptoms may shed further light 
on how seasonality influences these menopausal symptoms.
Longitudinal data from annual interviews in SWAN estimated the average duration of hot 
flashes (time between first reported and last reported period of hot flashes occurring 6 or 
more days over a 2 week period) to be 7.4 years (33). The Penn Ovarian Aging (POA) study 
reported an average hot flash duration of 10.2 years (34). Both studies documented 
important differences in duration based on timing of onset in relation to stage of 
reproductive aging. The duration for women who first experienced hot flashes in the late 
transition/postmenopause was 3.4 and 3.8 years, respectively. SWAN (35) and other studies 
(36) have documented that subgroups of women differ in the timing and trajectory of their 
hot flash experience while the POA study reported a correlation between FSH variability and 
women’s hot flash trajectories (37). In future studies, longitudinal assessment of melatonin 
levels in SWAN using stored urine specimens may enhance understanding of relationships 
between change in melatonin levels with ovarian aging and risk of menopausal symptoms.
Availability of monthly calendar data made it possible to model the trajectory of change in 
symptoms in relation to proximity of the FMP more precisely. The current analysis of 
monthly symptom data again documents that a significant proportion of women experienced 
symptoms many years before the FMP, yet we identified a sharp increase in the prevalence 
of symptom reporting coincident with the FMP. This large jump in prevalence is particularly 
notable since symptoms were recorded prospectively and women would not have been aware 
when they reported symptoms that the menstrual period reported in a given month was in 
fact their FMP. This finding provides further evidence that the FMP is a salient marker of 
menopause, associated with an observable impact on symptom reporting in the month the 
FMP occurs. Notably, HT use was associated with a stronger reduction in hot flashes, night 
sweats and trouble sleeping after the FMP than before. This pattern of symptom onset and 
varying responsiveness to HT use suggests that attribution of symptoms to menopause, while 
clearly appropriate for some women, may not be an appropriate attribution for the symptom 
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experience of all women. Future studies should evaluate alternative explanations and 
biological mechanisms for vasomotor symptoms and sleep complaints that begin several 
years before and continue several years after the menopause.
Consistent with other studies of midlife women (33, 34), current smokers were more likely 
to report all three symptoms, Black women were more likely and Japanese women were 
least likely to report hot flashes and night sweats, and white women were most likely to 
report trouble sleeping across time. However, none of these covariates significantly 
influenced the observed seasonal variation.
This study has some limitations. We indexed symptom experience to the date of FMP, thus 
included only women observed to have a natural menopause. Women whose FMP was 
masked by HT use, who are likely to have been the most symptomatic, were excluded which 
may have resulted in selection bias. We had information on occurrence but not severity of 
symptoms. Nonetheless, this study had several strengths including the availability of 
prospectively recorded and frequent monthly assessment of symptoms for up to 10 years, the 
ability to index symptoms by months before and after the FMP, and ability to control for 
other risk factors for menopausal symptoms.
CONCLUSIONS
It is estimated that 40–80% of women report vasomotor symptoms during the menopausal 
transition with the potential for significant adverse impact on quality of sleep and quality of 
life. (11, 27, 38, 39) Prospectively collected monthly symptom reports allowed us to account 
for seasonal variation of menopausal symptom reporting and to examine change in reporting 
closely aligned to the date of the FMP. These data revealed for the first time the temporal 
impact of the FMP per se on symptom experience, with trouble sleeping, night sweats and 
most notably hot flashes increasing sharply at the time of the FMP. Modelling of seasonal 
variation revealed increases in symptom reporting associated with the summer solstice and 
troughs with the winter solstice. These data underscore the need for clinicians to consider 
the summer as critical time with respect to the occurrence of symptoms and needs for their 
management. Reducing current gaps in knowledge of the factors and mechanisms related to 
experience of menopausal symptoms are central to the development of interventions and of 
treatment to reduce these symptoms.
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Figure 1: 
Histograms of the monthly prevalence of hotflashes, night sweats, and trouble sleeping in 
relation to time before and after the final menstrual period (FMP): the Study of Women’s 
Health Across the Nation (SWAN) (n=955).
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Figure 2. 
Odds ratio for reporting of hot flash, night sweats, and trouble sleeping by month, the Study 
of Women’s Health Across the Nation (SWAN) (n=955). Peaks for hot flash and trouble 
sleeping reporting occur in July and for night sweats in May while troughs occur in January 
and November, respectively.
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Figure 3. 
Estimated within-woman trends in the probability of reporting hot flashes, night sweats and 
trouble sleeping in relation to time before and after the final menstrual period (FMP) by 
smoking status at baseline, race/ethnicity and ever hormone use, the Study of Women’s 
Health Across the Nation (SWAN) (n=955).
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Table 1:
Descriptive Characteristics of Study Participants, the Study of Women’s Health Across the Nation (SWAN) 
Menstrual Calendar substudy (n=955).
Frequency
N Percent
Race/Ethnicity
 Black 245 25.7%
 White 401 42.0%
 Chinese 147 15.4%
 Japanese 162 17.0%
Education
 Less than High School 54 5.7%
 High School 161 17.0%
 Some Post High School 308 32.5%
 College 216 22.8%
 Post College 208 22.0%
 Missing 8
Difficulty Paying for Basics
 Very Hard 73 7.8%
 Somewhat Hard 267 28.4%
 Not Hard 599 63.8%
 Missing 16 --
Smoking
 Never Smoker 578 60.8%
 Past Smoker 227 23.9%
 Current Smoker 145 15.3%
 Missing 5 --
HT use during study period
 No 748 78.4%
 Yes 206 21.6%
 Missing 1
Site
 Michigan 245 25.7%
 Boston 217 22.7%
 Oakland 241 25.2%
 Los Angeles 252 26.4%
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